Boehringer Ingelheim’s weight-loss drug candidate ... dysfunction-associated steatotic liver disease (MASLD), which in turn has been rebranded from non-alcoholic fatty liver disease (NAFLD).

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

The chronic and progressive inflammatory disease bronchiectasis is characterised by permanent bronchi dilation and by ...

The heritage of Boehringer Ingelheim in developing ... leading to widening of the airways, which, in turn, improves expiratory flow 3. Since obstruction of the airways and associated symptoms ...

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over ...

Hosted by Boehringer Ingelheim, the ‘CRM Summit’, an expert engagement ... 1 accounting for up to 20 million deaths annually.2,3 The intricate connection between the CRM systems signifies that disease ...

She's currently the Chief Medical Officer and Head of Medicine at Boehringer Ingelheim. Well ... meaning that we are looking to turn cold tumors into hot tumors. And we do that through cancer ...

The global Cattle & Porcine/Swine Reproductive Diseases market is expected to grow to USD 975.8 Million by 2029, up from USD ...

Lenders report that default rates on secured loans to UK households increased in Q3 2024 and are expected to increase again ...

Germany, Norway, Luxembourg, Denmark, and Ireland made the biggest new commitments to WHO funding.View on euronews ...

Researchers from the School of Veterinary Medicine and Perelman School of Medicine have found that YY1 knockout pro-B cells can generate T lineage cells helping B cells produce antibodies.

By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.